Article Text

AB0518 Clinical Thrombotic Manifestations in SLE Patients with and without Antiphospholipid Antibodies: A Ten-Year Follow-Up
  1. T. Tarr1,
  2. N. Nagy1,
  3. E. Cserép2,
  4. M. Zeher1
  1. 1Division of Clinical Immunology
  2. 2Division of Psychiatric, University of Debrecen, Debrecen, Hungary


Background Systemic lupus eyrthematosus can bge associated with antiphospholipid syndrome. Years ago our study team investigated the thrombotic risk factors and complications in 272 lupus patients with and without antiphospholipid antibodies. At baseline, three groups were created, an aPL- group with 107 aPL negative patients, an aPL+ group with 81 aPL positive patients without clinical manifestations and a secondary antiphospholipid syndrome (APS) group with 84 aPL+ patients who met the Sapporo criteria.

Objectives The objective of this study was to investigate of new thrombotic events, SLE activity,.co-morbidities, and mortality in total of 272 lupus patients for ten years of follow up.

Methods The above mentioned 272 patients with SLE registerered in the Division of Clinical Immunology, University of Debrecen have been followed up prospectively for ten years.

Results A total of 28 out of the 272 patients were lost to follow up. A total of 22 new thrombotic complicatons occurred, two in the aPL negative group, three in the aPL+ group. New antiphospholipid antibodies appeared in these patients. 77.3% of the new thrombotic complicatins reoccurred in the APS group despite the adequat anticoagulant and/or anti-platlet therapy. SLE activity was the most common in the APL+ group but the difference was not significant. A total of 27 out of 84 APS (32%), 14 out of 81 aPL positive and 10 out of 107 aPL negative patients died during the follow up. The causes of death were thrombotic events or complications in 40.7% in patients with APS.

Conclusions Our data confirm recurring thrombotic events in lupus patients with antiphospholipid syndrome. Antiphospholipid syndrome seems to negatively influence the survival of the patients with systemic lupus erythematosus.

Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.